{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:25:18Z","timestamp":1769840718367,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clon.2025.103895","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T13:54:30Z","timestamp":1750254870000},"page":"103895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Tumour-Specific Growth Rate as a Potential Predictor of Outcomes in Oligoprogressive Disease Treated With Stereotactic Body Radiotherapy"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-2461","authenticated-orcid":false,"given":"I.","family":"Navarro-Domenech","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Helou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kuruvilla Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hosni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Glicksman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Javor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6793-2863","authenticated-orcid":false,"given":"A.J.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2025.103895_bib1","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib2","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2025.103895_bib4","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6449-8","article-title":"Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer","volume":"19","author":"Kissel","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2025.103895_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.lungcan.2018.08.005","article-title":"Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?","volume":"124","author":"Merino Lara","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2025.103895_bib8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.radonc.2019.08.018","article-title":"Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter","volume":"142","author":"Thompson","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib9","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s12094-021-02553-5","article-title":"Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy","volume":"23","author":"Ingrosso","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.radonc.2018.04.022","article-title":"Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression","volume":"127","author":"Pembroke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41416-020-01128-5","article-title":"Metastasis-directed therapy for oligometastasis and beyond","volume":"124","author":"Beckham","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2025.103895_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JOP.2016.018846","article-title":"Altering the natural history of oligometastatic prostate cancer with local therapies: Reality versus illusion","volume":"13","author":"Tran","year":"2017","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clon.2025.103895_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2014.96","article-title":"The oligometastatic state\u2014separating truth from wishful thinking","volume":"11","author":"Palma","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110505","article-title":"Stereotactic ablative radiotherapy for oligoprogressive solid tumours: A systematic review and meta-analysis","volume":"200","author":"Tan","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110288","article-title":"Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer","volume":"196","author":"Doyle","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110565","article-title":"Beyond lesion count: Emphasizing disease pace in oligometastatic management","volume":"201","author":"Chang","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib17","article-title":"The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial","author":"Glicksman","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2025.103895_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/1759-7714.13744","article-title":"Validating impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy","volume":"12","author":"Atallah","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.clon.2025.103895_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-021-00858-8","article-title":"[18F]FMCH PET\/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer","volume":"11","author":"Sollini","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.clon.2025.103895_bib20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3171\/2021.3.SPINE201534","article-title":"Radiomic modeling to predict risk of vertebral compression fracture after stereotactic body radiation therapy for spinal metastases","volume":"36","author":"Gui","year":"2022","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.clon.2025.103895_bib21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3857\/roj.2021.00311","article-title":"Computed tomography-based radiomic model predicts radiological response following stereotactic body radiation therapy in early-stage non-small-cell lung cancer and pulmonary oligo-metastases","volume":"39","author":"Cheung","year":"2021","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.clon.2025.103895_bib22","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/mp.14200","article-title":"Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study","volume":"47","author":"Simpson","year":"2020","journal-title":"Med Phys"},{"key":"10.1016\/j.clon.2025.103895_bib23","volume":"8","author":"Bassukas\u223cf","year":"1990"},{"key":"10.1016\/j.clon.2025.103895_bib24","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/pros.23508","article-title":"A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases","volume":"78","author":"Linxweiler","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.clon.2025.103895_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144144","article-title":"In Vivo Tumor Growth Rate Measured by US in Preoperative Period and Long Term Disease Outcome in Breast Cancer Patients","volume":"10","author":"Yoo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clon.2025.103895_bib26","doi-asserted-by":"crossref","unstructured":"Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, et al. Pre-treatment tumor-specific growth rate as a temporal biomarker that predicts treatment failure and improves risk stratification for oropharyngeal cancer n.d. https:\/\/doi.org\/10.1016\/j.oraloncology.2015.09.001.","DOI":"10.1016\/j.oraloncology.2015.09.001"},{"key":"10.1016\/j.clon.2025.103895_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025359","article-title":"Specific growth rates calculated from CTs in patients with head and neck squamous cell carcinoma: a retrospective study performed in Austria","volume":"9","author":"Dejaco","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.clon.2025.103895_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1061881","article-title":"Mathematical prediction with pretreatment growth rate of metastatic cancer on outcomes: implications for the characterization of oligometastatic disease","volume":"13","author":"Shin","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib29","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/PO.21.00172","article-title":"Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor","volume":"5","author":"Nishino","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clon.2025.103895_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.21037\/atm.2019.02.14","article-title":"Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancer","volume":"7","author":"Osorio","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clon.2025.103895_bib31","article-title":"Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy","author":"Chen","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2025.103895_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100179","article-title":"Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer","volume":"6","author":"Kato","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.clon.2025.103895_bib33","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer n.d.;45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"10.1016\/j.clon.2025.103895_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4682-11-21","article-title":"Analysis of inter-patient variations in tumour growth rate","volume":"11","author":"Mehrara","year":"2014","journal-title":"Theor Biol Med Model"},{"key":"10.1016\/j.clon.2025.103895_bib35","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1016\/j.cllc.2015.05.008","article-title":"Classification and reporting of late radiographic changes after lung stereotactic body radiotherapy: Proposing a new system","volume":"16","author":"Raziee","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clon.2025.103895_bib36","doi-asserted-by":"crossref","unstructured":"Kim J, Suk Chang J, Sung W, Sung Kim J, Hyung Kim T, Hee Choi S, et al. A Comparison of 2 Disease Burden Assessment Methods (3D Volume Versus the Number of Lesions) for Prognostication of Survival in Metastatic Melanoma: Implications for the Characterization of Oligometastatic Disease n.d. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.08.040.","DOI":"10.1016\/j.ijrobp.2022.08.040"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525001505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525001505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:36:56Z","timestamp":1762331816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655525001505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":36,"alternative-id":["S0936655525001505"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2025.103895","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumour-Specific Growth Rate as a Potential Predictor of Outcomes in Oligoprogressive Disease Treated With Stereotactic Body Radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2025.103895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103895"}}